Business Context and Reporting Period
Company: Innate Pharma S.A.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Month of May 2020
Date of Report: May 20, 2020
Principal Executive Office: 117 Avenue de Luminy, 13009 Marseille, France
This filing serves as a cover document for a press release dated May 20, 2020 (Exhibit 99.1). The registrant files annual reports under Form 20-F.
Key Financial Metrics
The provided filing text is a cover sheet and does not contain specific financial data. Consequently, the following metrics are not available in this document:
- Revenue
- Profit/Loss
- Cash Flow
- Margins
- Debt Levels
- Liquidity Position
Note: The filing text does not provide a clear value for any financial metric.
Material Changes
The filing text does not disclose specific material changes versus prior periods. The document references a press release (Exhibit 99.1) which likely contains the details of the event or update being reported, but the content of that release is not included in the provided text.
Guidance, Outlook, and Risks
No guidance, outlook, management commentary, risks, contingencies, or unusual items are detailed in the provided filing text. The document is limited to administrative details and the signature of the Chief Financial Officer, Laure-Hélène Mercier.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated May 20, 2020) to understand the specific event triggering this 6-K filing.
- Consult the most recent Form 20-F or quarterly reports for actual financial performance data, as this 6-K contains none.
- Verify if the press release contains updates on clinical trial progress, regulatory approvals, or partnership agreements, which are common drivers for 6-K filings in biotechnology firms.